Results 21 to 30 of about 33,952 (165)

Efficacy of rFVIIIFc versus Emicizumab for the Treatment of Patients with Hemophilia A without Inhibitors: Matching-Adjusted Indirect Comparison of A-LONG and HAVEN Trials

Journal of Blood Medicine, 2021
Robert Klamroth,1 Piotr Wojciechowski,2 Samuel Aballéa,3 Françoise Diamand,4 Zalmai Hakimi,5 Jameel Nazir,5 Lydia Abad-Franch,6 Stefan Lethagen,7 Elena Santagostino,8 Michael D Tarantino9 1Department of Internal Medicine, Hemophilia ...
Klamroth R, Wojciechowski P, Aballéa S, Diamand F, Hakimi Z, Nazir J, Abad-Franch L, Lethagen S, Santagostino E, Tarantino MD   +9 more
doaj  

Perspective: Designing T-Cell Engagers With Better Therapeutic Windows

Frontiers in Oncology, 2020
This perspective highlights the history and challenges of developing CD3-based bispecific T-cell engagers (TCEs) as cancer therapeutics as well as considerations and potential strategies for designing the next generation TCE molecules.
Omid Vafa, Nathan D. Trinklein
doaj   +1 more source

Design and engineering of bispecific antibodies: insights and practical considerations

Frontiers in Bioengineering and Biotechnology
Bispecific antibodies (bsAbs) have attracted significant attention due to their dual binding activity, which permits simultaneous targeting of antigens and synergistic binding effects beyond what can be obtained even with combinations of conventional ...
Andreas V. Madsen, Lasse E. Pedersen, Peter Kristensen, Steffen Goletz   +3 more
doaj   +1 more source

Phase 1, first-in-human study of TYRP1-TCB (RO7293583), a novel TYRP1-targeting CD3 T-cell engager, in metastatic melanoma: active drug monitoring to assess the impact of immune response on drug exposure

Frontiers in Oncology
IntroductionAlthough checkpoint inhibitors (CPIs) have improved outcomes for patients with metastatic melanoma, those progressing on CPIs have limited therapeutic options.
Anna Spreafico, Eva Muñoz Couselo, Anja Irmisch, Juliana Bessa, George Au-Yeung, Oliver Bechter, Inge Marie Svane, Miguel F. Sanmamed, Miguel F. Sanmamed, Valentina Gambardella, Valentina Gambardella, Meredith McKean, Margaret Callahan, Reinhard Dummer, Christian Klein, Pablo Umaña, Nicole Justies, Florian Heil, Linda Fahrni, Eugenia Opolka-Hoffmann, Inja Waldhauer, Conrad Bleul, Roland F. Staack, Vaios Karanikas, Stephen Fowler   +24 more
doaj   +1 more source

Mammalian Display Platform for the Maturation of Bispecific TCR-Based Molecules

Antibodies, 2022
Bispecific T cell receptor (TCR)-based molecules capable of redirecting and activating T cells towards tumor cells represent a novel and promising class of biotherapeutics for the treatment of cancer. Usage of TCRs allows for targeting of intracellularly
Janine Dilchert, Martin Hofmann, Felix Unverdorben, Roland Kontermann, Sebastian Bunk   +4 more
doaj   +1 more source

THE ALBUMIN-BINDING DOMAIN AS A SCAFFOLD FOR PROTEIN ENGINEERING

Computational and Structural Biotechnology Journal, 2013
The albumin-binding domain is a small, three-helical protein domain found in various surface proteins expressed by gram-positive bacteria. Albumin binding is important in bacterial pathogenesis and several homologous domains have been identified.
Johan Nilvebrant, Sophia Hober
doaj   +1 more source

Modular generation of multispecific antibodies using protein trans-splicing

mAbs
Multispecific antibodies are exhibiting rapid growth in drug development due to their ability to engage multiple therapeutic targets and deliver unique functional properties inaccessible to conventional monoclonal antibodies.
Jared A. Shadish, John D. Bagert, Amber N. Lee, Kenneth K. Sharp, Chunning Yang, Yijia Li, Rui Wang, Seungwook Shin, Alina A. Malik, Jia Lin, Fengying Huang, Wenhai Liu, Yariv Mazor   +12 more
doaj   +1 more source

Molecular Mechanism of HER2 Rapid Internalization and Redirected Trafficking Induced by Anti-HER2 Biparatopic Antibody

Antibodies, 2020
Amplification and overexpression of HER2 (human epidermal growth factor receptor 2), an ErbB2 receptor tyrosine kinase, have been implicated in human cancer and metastasis.
Jackie Cheng, Meina Liang, Miguel F. Carvalho, Natalie Tigue, Raffaella Faggioni, Lorin K. Roskos, Inna Vainshtein   +6 more
doaj   +1 more source

Robust production of monovalent bispecific IgG antibodies through novel electrostatic steering mutations at the CH1-Cλ interface

mAbs, 2023
Bispecific antibodies represent an increasingly large fraction of biologics in therapeutic development due to their expanded scope in functional capabilities.
John D. Bagert, Vaheh Oganesyan, Chi-I Chiang, Mike Iannotti, Jia Lin, Chunning Yang, Sterling Payne, Will McMahon, Samuel Edwards, Andrew Dippel, Mark Hutchinson, Fengying Huang, Vineela Aleti, Chendi Niu, Chen Qian, Jessica Denham, Sofia Ferreira, Pallab Pradhan, Mark Penney, Chunlei Wang, Wenhai Liu, Even Walseng, Yariv Mazor   +22 more
doaj   +1 more source

The proximity of the N- and C- termini of bovine knob domains enable engineering of target specificity into polypeptide chains

mAbs, 2022
Cysteine-rich knob domains can be isolated from the ultralong heavy-chain complementarity-determining region (CDR) 3, which are unique to a subset of bovine antibodies, to create antibody fragments of ~4 kDa.
Alice Hawkins, Callum Joyce, Kevin Brady, Adam Hold, Alan Smith, Michael Knight, Conor Howard, Jean van den Elsen, Alastair D.G. Lawson, Alex Macpherson   +9 more
doaj   +1 more source